University of Sfax-Department of Thoracic and Cardiovascular Surgery, Habib Bourguiba University Hospital, Sfax, Tunisia.
Department of General and Thoracic Surgery, Rouen University Hospital, Normandy, France.
Interact Cardiovasc Thorac Surg. 2022 Jun 1;34(6):1016-1023. doi: 10.1093/icvts/ivab287.
Our goal was to report our midterm results using imaging-assisted modalities with robotic segmentectomies for non-small-cell lung cancer (NSCLC).
This was a retrospective study of all robotic segmentectomies, with confirmed NSCLC, performed at our general and thoracic surgery unit in the Rouen University Hospital (France), from January 2012 through December 2019. Benign and metastatic lesions were excluded. Data were extracted from the EPITHOR French nationwide database.
A total of 121 robotic segmentectomies were performed for 118 patients with a median age of 65 (interquartile range: 60, 69) years. The majority had clinical stage T1aN0M0 (71.9%) or T1bN0M0 (13.2%). The mean (standard deviation) number of resected segments was 1.93 (1.09) with 80.2% imaging-assisted segmentectomies. Oriented (according to tumour location) or systematic lymphadenectomy or sampling was performed for 72.7%, 23.1% and 4.1% of patients. The postoperative course was uneventful for 94 patients (77.7%), whereas 34 complications occurred for 27 patients (22.3%), including 2 patients (1.7%) with Clavien-Dindo ≥III complications. The mean thoracic drainage duration was 4.12 days, and the median hospital stay was 4 days (interquartile range: 3, 5) after the operation. The 2-year survival rate was 93.9% (95% confidence interval: 86.4-97.8%). Excluding stage IV (n = 3) and stage 0 tumours (n = 6), the 2-year survival rate was 95.7% (95% confidence interval: 88.4-98.8%) compared to an expected survival rate of 94.0% according to stage-specific survival rates found in a large external reference cohort.
Imaging-guided robotic-assisted thoracic surgery segmentectomy seems to be useful and oncological with good midterm results, especially for patients with early-stage NSCLC.
我们旨在报告使用影像辅助机器人肺段切除术治疗非小细胞肺癌(NSCLC)的中期结果。
这是一项回顾性研究,纳入了 2012 年 1 月至 2019 年 12 月在法国鲁昂大学医院普通和胸外科进行的所有经确认患有 NSCLC 的机器人肺段切除术。良性和转移性病变被排除在外。数据来自 EPITHOR 法国全国数据库。
共对 118 例患者进行了 121 例机器人肺段切除术,中位年龄为 65 岁(四分位距:60,69)。大多数患者为临床分期 T1aN0M0(71.9%)或 T1bN0M0(13.2%)。切除的肺段数平均为 1.93(1.09),80.2%为影像学辅助肺段切除术。根据肿瘤位置进行定向(或系统性)淋巴结切除术或采样,分别用于 72.7%、23.1%和 4.1%的患者。94 例患者(77.7%)术后无并发症,27 例患者(22.3%)发生 34 种并发症,其中 2 例(1.7%)为 Clavien-Dindo≥III 级并发症。胸腔引流时间平均为 4.12 天,术后中位住院时间为 4 天(四分位距:3,5)。2 年生存率为 93.9%(95%置信区间:86.4-97.8%)。排除 IV 期(n=3)和 0 期肿瘤(n=6)后,2 年生存率为 95.7%(95%置信区间:88.4-98.8%),高于根据大型外部参考队列中特定分期生存率得出的预期生存率 94.0%。
影像学引导的机器人辅助胸部手术肺段切除术似乎是有用的,且具有良好的中期结果,尤其是对于早期 NSCLC 患者。